Sinusitis and pneumonia hospitalization after introduction of pneumococcal conjugate vaccine

Pediatrics

Volumn 134, Issue 6, 2014, Pages e1528-e1536

  Lindstrand, Ann ^a,b   Bennet, Rutger ^b   Galanis, Ilias ^a   Blennow, Margareta ^b,c   Ask, Lina Schollin ^c   Dennison, Sofia Hultman ^b   Rinder, Malin Ryd ^c   Eriksson, Margareta ^b   Henriques Normark, Birgitta ^a,b,d   Örtqvist, Åke ^d,e   Alfvén, Tobias ^b,c  

^a SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c STOCKHOLM SÖDER HOSPITAL   (Sweden)

^d KAROLINSKA INSTITUTE   (Sweden)

^e STOCKHOLM COUNTY COUNCIL   (Sweden)

Author keywords

Pneumococcal conjugated vaccine; Pneumonia; Sinusitis; Streptococcus pneumoniae

Indexed keywords

PNEUMOCOCCUS VACCINE; HEPTAVALENT PNEUMOCOCCAL CONJUGATE VACCINE; PREVENAR13; VACCINE;

ADOLESCENT; ARTICLE; BACTERIAL PNEUMONIA; CHILD; CHILD HOSPITALIZATION; COMPARATIVE STUDY; CONTROLLED STUDY; EMPYEMA; HOSPITAL DISCHARGE; HUMAN; INCIDENCE; INFANT; PNEUMONIA; POPULATION RESEARCH; RETROSPECTIVE STUDY; SINUSITIS; SWEDEN; TREND STUDY; VACCINATION; CROSS-SECTIONAL STUDY; FEMALE; HOSPITALIZATION; IMMUNOLOGY; MALE; NEWBORN; PNEUMOCOCCAL INFECTIONS; PNEUMONIA, PNEUMOCOCCAL; PRESCHOOL CHILD; STATISTICS AND NUMERICAL DATA;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; FEMALE; HOSPITALIZATION; HUMANS; INFANT; INFANT, NEWBORN; MALE; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; PNEUMONIA, PNEUMOCOCCAL; SINUSITIS; SWEDEN; VACCINES, CONJUGATE;

EID: 84913554604     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2013-4177     Document Type: Article

References (40)

1. O'Brien KL, Wolfson LJ, Watt JP, et al; Hib and Pneumococcal Global Burden of Disease Study Team. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet. 2009;374(9693):893-902
2. Liu L, Johnson HL, Cousens S, et al; Child Health Epidemiology Reference Group of WHO and UNICEF. Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000. Lancet. 2012;379(9832): 2151-2161
3. Nair H, Simões EAF, Rudan I, et al; Severe Acute Lower Respiratory Infections Working Group. Global and regional burden of hospital admissions for severe acute lower respiratory infections in young children in 2010: a systematic analysis. Lancet. 2013; 381(9875):1380-1390
4. Walker CL, Rudan I, Liu L, et al. Global burden of childhood pneumonia and diarrhoea. Lancet. 2013;381(9875):1405-1416
5. Wald ER, Applegate KE, Bordley C, et al; American Academy of Pediatrics. Clinical practice guideline for the diagnosis and management of acute bacterial sinusitis in children aged 1 to 18 years. Pediatrics. 2013;132(1). Available at: www.pediatrics.org/cgi/content/full/132/1/e262
6. Benninger M, Brook I, Farrell DJ. Disease severity in acute bacterial rhinosinusitis is greater in patients infected with Streptococcus pneumoniae than in those infected with Haemophilus influenzae. Otolaryngol Head Neck Surg. 2006;135(4): 523-528
7. Lucero MG, Dulalia VE, Nillos LT, et al. Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and X-ray defined pneumonia in children less than two years of age. Cochrane Database Syst Rev. 2009; (4): CD004977
8. Fitzwater SP, Chandran A, Santosham M, Johnson HL. The worldwide impact of the seven-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2012;31(5):501-508
9. Koshy E, Murray J, Bottle A, Sharland M, Saxena S. Impact of the seven-valent pneumococcal conjugate vaccination (PCV7) programme on childhood hospital admissions for bacterial pneumonia and empyema in England: national time-trends study, 1997-2008. Thorax. 2010;65(9):770-774
10. Nelson JC, Jackson M, Yu O, et al. Impact of the introduction of pneumococcal conjugate vaccine on rates of community acquired pneumonia in children and adults. Vaccine. 2008;26(38):4947-4954
11. Lee GE, Lorch SA, Sheffler-Collins S, Kronman MP, Shah SS. National hospitalization trends for pediatric pneumonia and associated complications. Pediatrics. 2010;126(2):204-213
12. Elston JW, Santaniello-Newton A, Meigh JA, et al. Increasing incidence of invasive pneumococcal disease and pneumonia despite improved vaccination uptake: surveillance in Hull and East Yorkshire, UK, 2002-2009. Epidemiol Infect. 2012;140(7): 1252-1266
13. Benninger MS, Manz R. The impact of vaccination on rhinosinusitis and otitis media. Curr Allergy Asthma Rep. 2010;10(6):411-418
14. Shapiro DJ, Gonzales R, Cabana MD, Hersh AL. National trends in visit rates and antibiotic prescribing for children with acute sinusitis. Pediatrics. 2011;127 (1):28-34
15. Fanella S, Singer A, Embree J. Presentation and management of pediatric orbital cellulitis. Can J Infect Dis Med Microbiol. 2011; 22(3):97-100
16. Stockholm County Child Healthcare Services. Annual Report. Stockholm, Sweden: Stockholm County Child Healthcare Services; 2012
17. Regional Planning Office. Official statistics, Stockholm County Council. Available at: www.tmr.sll.se/Global/Dokument/Statistik/Befolkningsutveckling/2012-1-s-Befolkningsutvecklingen-2011.pdf
18. Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther. 2002;27(4):299-309
19. Gebski V, Ellingson K, Edwards J, Jernigan J, Kleinbaum D. Modelling interrupted time series to evaluate prevention and control of infection in healthcare. Epidemiol Infect. 2012;140(12):2131-2141
20. Peña MT, Preciado D, Orestes M, Choi S. Orbital complications of acute sinusitis: changes in the post-pneumococcal vaccine era. JAMA Otolaryngol Head Neck Surg. 2013;139(3):223-227
21. Benninger MS. Acute bacterial rhinosinusitis and otitis media: changes in pathogenicity following widespread use of pneumococcal conjugate vaccine. Otolaryngol Head Neck Surg. 2008;138(3):274-278
22. McNeil JC, Hulten KG, Mason EO Jr, Kaplan SL. Serotype 19A is the most common Streptococcus pneumoniae isolate in children with chronic sinusitis. Pediatr Infect Dis J. 2009;28(9):766-768
23. Feikin DR, Kagucia EW, Loo JD, et al; Serotype Replacement Study Group. Serotypespecific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites. PLoS Med. 2013; 10(9):e1001517
24. Brook I, Gober AE. Frequency of recovery of pathogens from the nasopharynx of children with acute maxillary sinusitis before and after the introduction of vaccination with the 7-valent pneumococcal vaccine. Int J Pediatr Otorhinolaryngol. 2007;71(4):575-579
25. Magnus MC, Vestrheim DF, Nystad W, et al. Decline in early childhood respiratory tract infections in the Norwegian mother and child cohort study after introduction of pneumococcal conjugate vaccination. Pediatr Infect Dis J. 2012;31 (9):951-955
26. Griffin MR, Zhu Y, Moore MR, Whitney CG, Grijalva CGUS. U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination. N Engl J Med. 2013;369(2): 155-163
27. Grijalva CG, Nuorti JP, Arbogast PG, Martin SW, Edwards KM, Griffin MR. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet. 2007;369(9568): 1179-1186
28. Grijalva CG, Griffin MR. Unveiling the burden of influenza-associated pneumococcal pneumonia. J Infect Dis. 2012;205(3):355-357
29. Viasus D, Paño-Pardo JR, Pachón J, et al; Novel Influenza A(H1N1) Study Group of the Spanish Network for Research in Infectious Diseases (REIPI). Pneumonia complicating pandemic (H1N1) 2009: risk factors, clinical features, and outcomes. Medicine (Baltimore). 2011;90(5):328-336
30. Weinberger DM, Simonsen L, Jordan R, Steiner C, Miller M, Viboud C. Impact of the 2009 influenza pandemic on pneumococcal pneumonia hospitalizations in the United States. J Infect Dis. 2012;205(3): 458-465
31. Örtqvist A, Bennet R, Rinder MR, Lindblad H, Eriksson M. Effectiveness of the monovalent AS03-adjuvanted influenza A(H1N1)pdm09 vaccine against hospitalization in children because of influenza. Vaccine. 2012;30(39): 5699-5702
32. Madhi SA, Klugman KP; Vaccine Trialist Group. A role for Streptococcus pneumoniae in virus-associated pneumonia. Nat Med. 2004;10(8):811-813
33. Weinberger DM, Givon-Lavi N, Shemer-Avni Y, et al. Influence of pneumococcal vaccines and respiratory syncytial virus on alveolar pneumonia, Israel. Emerg Infect Dis. 2013; 19(7):1084-1091
34. Grijalva CG, Zhu Y, Nuorti JP, Griffin MR. Emergence of parapneumonic empyema in the USA. Thorax. 2011;66(8):663-668
35. Grijalva CG, Nuorti JP, Zhu Y, Griffin MR. Increasing incidence of empyema complicating childhood community-acquired pneumonia in the United States. Clin Infect Dis. 2010;50(6):805-813
36. Burgos J, Falcó V, Pahissa A. The increasing incidence of empyema. Curr Opin Pulm Med. 2013;19(4):350-356
37. Li ST, Tancredi DJ. Empyema hospitalizations increased in US children despite pneumococcal conjugate vaccine. Pediatrics. 2010;125(1):26-33
38. Roca A, Sigaúque B, Quintó L, et al. Estimating the vaccine-preventable burden of hospitalized pneumonia among young Mozambican children. Vaccine. 2010;28(30):4851-4857
39. Cutts FT, Zaman SM, Enwere G, et al; Gambian Pneumococcal Vaccine Trial Group. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebocontrolled trial. Lancet. 2005;365(9465): 1139-1146
40. Bhutta ZA, Das JK, Walker N, et al; Lancet Diarrhoea and Pneumonia Interventions Study Group. Interventions to address deaths from childhood pneumonia and diarrhoea equitably: what works and at what cost? Lancet. 2013;381(9875):1417-1429